Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
코로나19 환자에서 로피나비르/리토나비르의 집단 약동학
Article
[키워드] 50% effective concentration
age
Alanine
alanine aminotransferase
ALT
Analysis
aspartate
Aspartate aminotransferase
AST
BMI
body mass
body mass index
body weight
C reactive protein
Concentration
concentrations
coronavirus disease
Coronavirus disease 2019
covariate
covariates
COVID-19
creatinine
CRP
data set
described
develop
dose
effective
estimate
females
Final
Gender
Height
high variability
hospitalized patient
interval
Lopinavir
Lopinavir/ritonavir
males
median
mixed-effects modeling
parameter
Patient
patients
pharmacokinetic
pharmacokinetics
PK parameters
plasma concentration
Population
proportion
reduce
regimen
Ritonavir
SARS-CoV-2 virus
significant effect
Steady state
tested
Vero E6
Vero E6 cell
VERO E6 cells
was tested
[DOI] 10.1007/s00228-020-03020-w PMC 바로가기 [Article Type] Article
[DOI] 10.1007/s00228-020-03020-w PMC 바로가기 [Article Type] Article